Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib +/- Ruxolitinib in Myelofibrosis
NCT03144687Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of itacitinib in myelofibrosis (MF) (2 cohorts), sponsored by Incyte. Primary endpoints: Change in Spleen Volume at 24 weeks and Percentage Change in Spleen Volume at 24 weeks. Started Jan 2018; status: completed.
02
Drugs
itacitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03144687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144687.